Is the Immunopeptidome Getting Darker?: A Commentary on the Discussion around Mishto et al., 2019

Anthony W. Purcell*
Department of Biochemistry and Molecular Biology, and Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia

Keywords: HLA, mass spectrometry - LC-MS/MS, immunopeptidome, proteasome, spliced peptides

A Commentary on

Response: Commentary: An In Silico – In Vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients
By Mishto M, Rodriguez-Hernandez G, Neefjes J, Urlaub H and Liepe J (2021) Front. Immunol. 12:679836. doi: 10.3389/fimmu.2021.679836

INTRODUCTION

The immune system is perhaps the most ancient practitioner of proteomics; and as we delve into the more nuanced aspects of antigen processing and presentation, we learn more of the complexity of this essential process and into a debate amongst the human practitioners of immunopeptidomics threatens to boil over and confer reputational damage to both the field and the investigators who use this technique.

Traditionally the art of proteomics has used the identification of tryptic peptides to infer protein expression, a process termed “bottom-up” proteomics. Notably, an analogous process is used by antigen presenting cells to alert the immune system to the presence of infectious micro-organisms, malignancy and other abnormalities within the body. This process known as antigen processing and presentation relies on the selection of peptide fragments of antigens and their presentation on the surface of cells as a bound complex with Major Histocompatibility Complex (MHC) molecules. The isolation and characterisation of these MHC-bound peptides, most commonly through the use of liquid chromatography and mass spectrometry, is a rapidly growing field coined immunopeptidomics.

Immunopeptidomics as a field has rapidly matured in the past decade and has moved from the domain of just a handful of specialised laboratories to now being more generally applied by the proteomics and immunology communities. The genesis of immunopeptidomics can be traced back to early work of the groups of Don Hunt with Victor Englehard and Alessandro Sette (1–5) and Hans-Georg Rammensee (6–9). It was in the early 90’s that I joined the field and was immediately struck by the generosity and encouragement of the established investigators – sharing anecdotes, methods and solutions to problems with a focus on growing the discipline and answering key questions of immune specificity whilst untangling the complexity of antigen presentation. This is something I have never forgotten and it has inspired me to “give back” to the field happily training the numerous visitors to my laboratory and publishing our methodology widely and in great depth (10, 11).
Fast forwarding a few decades there have been drastic and exciting changes to the immunopeptidomics field. Improvements in instrumentation, nanoscale separation sciences and data acquisition have provided extremely rich datasets. The maturation of informatic approaches to handle this challenging data has also facilitated routine analysis of these non-tryptic peptides allowing thousands of confident identifications to be made. However, it is clear that there are still informatic challenges in the peptide-centric data analysis pipelines (12, 13) with a much lower proportion of spectra confidently assigned from immunopeptidomics data compared with more conventional samples such as tryptic digests of cell lysates. The search to explain these dark elements of the immunopeptidome has driven differences in interpretation and peptide sequence assignments to these MS/MS spectra (12, 14–25).

These issues are most apparent when it comes to the presence of post-translationally spliced peptides in the immunopeptidome. Their presence in the immunopeptidome first came to note with pioneering work from Jonathan Yewdell and James Yang (26) and Nathalie Vigneron and Benoit van den Eynde (27–31) linking these peptides with immune responses primarily in cancer, as also confirmed by others (21, 32). Conventional wisdom immediately decreed their existence and the proteasomal generation of such spliced peptides as being a rare event. Their presence in several other disease states has recently been reviewed (23, 33) but perhaps most surprisingly (and controversially) the frequency of these peptides in the HLA class I immunopeptidome was reported to be up to one third of all peptides identified isolated HLA peptide ligands (15). This ground-breaking study from Liepe and colleagues (15, 19) has been confirmed by some (16) and disputed by others (17). But what are the outcomes from this study and the subsequent response by the field? It has certainly shone a spotlight on the uncomfortably large proportion of peptides in the immunopeptidome that cannot be readily assigned using reference proteomes. It has also driven developments in the informatics used to search immunopeptidomics data with improvements in assignments of post-translational modifications (34, 35), incorporation of proteogenomics databases (36) and a series of alternative workflows to address the presence of spliced peptides (16, 18, 20–22, 24, 25, 37–42). However, no consensus has been reached with somewhere between 0 and 45% of peptides in the immunopeptidome believed to be spliced. As a field where we go from here is critical – we could polarize to one extreme or the other, sit on the fence or actually address the question of what is the source of these peptide antigens that comprise the dark immunopeptidome. It is clear that several possibilities are emerging to explain a proportion of these peptides (in addition to a proportion of spliced peptides) including unanticipated post-translational modifications (24); the presence of poorly annotated non-canonical sources of antigen such as small open reading frames, translated 5′ UTRs, exon–exon junctions, intronic regions, non-canonical reading frames or antisense transcripts all of which can potentially generate immunogenic non-canonical peptides (36, 43); endogenous retroviral elements (44), the presence of microbial peptides (45). Each source of non-canonical peptide will have its supporters and detractors but perhaps none are essentially wrong and the major limitation at present is the ability to differentiate between the various explanations for the experimentally acquired MS/MS data we generate?

It is also time as a field that we decide how we debate these issues and in my opinion time to stop subjectively re-searching others data but to design and implement our own experiments to more definitely corroborate or repudiate various sources of antigenic peptides in the immunopeptidome. Our field has made great strides and can look back at great community initiatives: the human immunopeptidome project (46) that strives to advance the documentation of peptides available for immune recognition in a variety of healthy and diseased states; minimal information requirements for an immunopeptidomics experiment (47) and HLA peptide atlases (48, 49) and data repositories (50) that have driven improvements in predictive algorithms and will provide the data required for the next generation of AI-based informatic tools (25). Let’s use this same spirit to explore the immunopeptidome and illuminate its dark side as a community united in this purpose.

AUTHOR CONTRIBUTIONS

AWP wrote this commentary.

ACKNOWLEDGMENTS

AP is a National Health and Medical Research Council of Australia Senior Research Fellow.

REFERENCES

1. Hunt DF, Michel H, Dickinson TA, Shabanowitz J, Cox AL, Sakaguchi K, et al. Peptides Presented to the Immune System by the Murine Class II Major Histocompatibility Complex Molecule I-A^d. Science (1992) 256:1817–20. doi: 10.1126/science.1319610
2. Henderson RAM H, Sakaguchi K, Shabanowitz J, Appela E, Hunt DF, Engelhard VH. HLA-A2.1-Associated Peptides From a Mutant Cell Line: A Second Pathway of Antigen Presentation. Science (1992) 255:1264–6. doi: 10.1126/science.1546329
3. Hunt DF, Henderson RA, Shabanowitz J, Sacaguchi K, Michel H, Sevilir N, et al. Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry. Science (1992) 255:1261–3. doi: 10.1126/science.1546328
4. Sette A, Ceman S, Kubo RT, Sakaguchi K, Appella E, Hunt DF, et al. Invariant Chain Peptides in Most HLA-DR Molecules of an Antigen-Processing Mutant. Science (1992) 258(5089):1801–4. doi: 10.1126/science.1465617
5. Henderson RA, Cox AL, Sakaguchi K, Appella E, Shabanowitz J, Hunt DF, et al. Direct Identification of an Endogenous Peptide Recognized by Multiple HLA-A2.1-Specific Cytotoxic T Cells. Proc Natl Acad Sci USA (1993) 90 (21): 10275–9. doi: 10.1073/pnas.90.21.10275
6. Rötzsche O, Falk K, Deres K, Schild H, Norda M, Metzger J, et al. Isolation and Analysis of Naturally Processed Viral Peptides as Recognized by Cytotoxic T Cells. Nature (1990) 348(6298):252–4. doi: 10.1038/348252a0
7. Falk K, Rötzsche O, Deres K, Metzger J, Jung G, Ramnsee H-G. Identification of Naturally Processed Viral Nonapeptides Allows Their Quantification in Infected Cells and Suggests an Allele-Specific T Cell Epitope Forecast. J Exp Med (1991) 174:425–34. doi: 10.1084/jem.174.2.425
5. Hanada K, Rotschke O, Stevanovic S, Jung G, Rammensee H-G. Allele-Specific Motifs Revealed by Sequencing of Self-Peptides Eluted From MHC Molecules. Nat Immunol (2003) 4(3):241–7. doi: 10.1038/nai.2003.20
6. Hanada K-L, Yewdell JW, Yang JC. Immune Recognition of a Human Renal Vigneron N, Stroobant V, Fonteneau J-F, Jotereau F, Van den Eynde BJ, et al. A Spliced Antigenic Peptide Comprising a Single Spliced Amino Acid Is Produced in the Proteasome by Reverse Splicing of a Longer Peptide Fragment Followed by Trimming. J Immunol (2014) 192(4):1962–71. doi: 10.4049/jimmunol.1302032
7. Vigneron N, Ferrari V, Stroobant V, Abbi Habib J, Van den Eynde BJ. Peptide Splicing by the Proteasome. J Biol Chem (2017) 292(51):21170–9. doi: 10.1074/jbc.R117.807560
8. Erhard F, Dölken L, Schilling B, Schlosser A. Identification of MHC-Bound Peptides for Immunopeptidomics. Nat Methods (2017) 14(5):513–20. doi: 10.1038/nmeth.4256
9. Erhard F, Dölken L, Schilling B, Schlosser A. Identiﬁcation of MHC-Bound Peptides for Immunopeptidomics. Nat Methods (2017) 14(5):513–20. doi: 10.1038/nmeth.4256
10. Pandey K, Ramarathinam SH, Purcell AW. Isolation of HLA Bound Peptides by Immunoonfﬁnity Capture and Identiﬁcation by Mass Spectrometry. Curr Protoc (2021) 1(3):e29. doi: 10.1002/cp1.92
11. Purcell AW, Ramarathinam SH, Ternette N. Mass Spectrometry-Based Identiﬁcation of MHC-Bound Peptides for Immunopeptidomics. Nat Methods (2019) 16(6):1687–707. doi: 10.1038/s41596-019-0133-y
12. Admon A. Are There Indeed Spliced Peptides in the Immunopeptidome? Mol Cell Proteomics (2021) 100099. doi: 10.1074/mcp.tm2000176
13. Faridi P, Purcell A, Croft N. In Immunopeptidomics We Need a Sniper Instead of a shotgun. Proteomics (2018) 18(12):7–7. doi: 10.1002/pmic.201700464
14. Haen SP, Løﬄer MW, Ramarathinam H-G, Brossart P. Towards New Horizons: Characterization, Classiﬁcation and Implications of the Tumour Antigenic Repertoire. Nat Rev Clin Oncol (2020) 17(10):595–610. doi: 10.1038/s41571-020-0387-x
15. Liepe J, Marino F, Sidney J, Jeko A, Bunting DE, Sette A, et al. A Large Fraction of HLA Class I Ligands Are Proteasome-Generated Spliced Peptides. Science (2016) 354(6310):354–8. doi: 10.1126/science.aaf6284
16. Faridi P, Li C, Ramarathinam SH, Vigneron N, Stroobant V, Van den Eynde BJ, et al. A Subset of HLA-I Peptides Are Not Genomically Templated: Evidence for cis- and Trans-Spliced Peptide Ligands. Sci Immunol (2018) 3(28):eaar3947. doi: 10.1126/sciimmunol.aar3947
17. Mylonas R, Beer I, Iseli C, Chong C, Pak HS, Gfeller D, et al. Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome. Mol Cell Proteomics (2018) 17(12):2347–57. doi: 10.1074/mcp.RA118.010087
18. Roﬂs Z, Solntsev SK, Shortreed MR, Frey BL, Smith LM. Global Identiﬁcation of Post-Translationally Spliced Peptides With Neo-Fusion. J Proteome Res (2018) 17(1):349–58. doi: 10.1021/acs.jproteome.8b00651
19. Liepe J, Sidney J, Lorenz FKM, Sette A, Mishto M. Mapping the MHC Class I- Spliced Immunopeptidome of Cancer Cells. Cancer Immunol Res (2019) 7(1):62–76. doi: 10.1158/2326-6066.CIR-18-0424
20. Erhard F, Dölken L, Schilling B, Schlosser A. Identiﬁcation of the Cryptic HLA-I Immunopeptidome. Cancer Immunol Res (2020) 8(8):1018–26. doi: 10.1158/2326-6066.CIR-19-0886
21. Faridi P, Woods K, Ostroumas S, Deceneux C, Arana H, Ruscharla D, et al. Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma. Cancer Immunol Res (2020) 8(10):1322–34. doi: 10.1158/2326-6066.CIR-19-0894
22. Mishto M. What We See, What We Do Not See, and What We Do Not Want To See in the HLA-I Immunopeptidome. Proteomics (2020) 12:e2000112. doi: 10.1002/pmic.202000112
23. Faridi P, Dorvah M, Purcell AW. Spliced HLA-Bound Peptides: A Black Swan Event in Immunology. Clin Exp Immunol (2021) 204(2):179–88. doi: 10.1111/cei.13589
24. Lichti CF. Identiﬁcation of Spliced Peptides in Pancreatic Islets Uncovers Errors Leading to False Assignments. Proteomics (2021) 21(78):e2000176. doi: 10.1002/pmic.202000176
25. Wilhelm M, Zölö DP, Graber M, Gessult S, Schmidt T, Schnaabum K, et al. Deep Learning Boosts Sensitivity of Mass Spectrometry-Based Immunopeptidomics. Nat Commun (2021) 12(1):336. doi: 10.1038/s41467-021-23713-9
26. Hanada K-L, Yewdell JW, Yang JC. Identiﬁcation of a Human Renal Cancer Antigen Through Post-Translational Protein Splicing. Nature (2004) 427(6971):252–6. doi: 10.1038/nature02240
27. Vigneron N, Stroobant V, Chapiero J, Ooms A, Degiovanni G, Morel S, et al. An Antigenic Peptide Produced by Peptide Splicing in the Proteasome. Science (2004) 304(5670):587–90. doi: 10.1126/science.1095552
28. Dalet A, Vigneron N, Stroobant V, Hanada K, Van den Eynde BJ. Splicing of Distant Peptide Fragments Occurs in the Proteasome by Transpeptidation and Produces the Spliced Antigenic Peptide Derived From Fibroblast Growth Factor-5. J Immunol (Baltimore Md: 1950) (2010) 184(6):3016–24. doi: 10.4049/jimmunol.1000174
29. Dalet A, Robbins PF, Stroobant V, Vigneron N, Li YF, El-Gamil M, et al. An Antigenic Peptide Produced by Reverse Splicing and Double Asparagine Deamidation. Proc Natl Acad Sci USA (2011) 108(29):E323–31. doi: 10.1073/pnas.1101892108
30. Michaelewicz, Larriee P, Stroobant V, Fonteneau J-F, Jotereau F, Van den Eynde BJ, et al. A Spliced Antigenic Peptide Comprising a Single Spliced Amino Acid Is Produced in the Proteasome by Reverse Splicing of a Longer Peptide Fragment Followed by Trimming. J Immunol (2014) 192(4):1962–71. doi: 10.4049/jimmunol.1302032
